--- title: Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake nct_id: NCT04957082 overall_status: COMPLETED phase: NA sponsor: Michigan State University study_type: INTERVENTIONAL primary_condition: SARS-CoV2 Infection countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04957082.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04957082" ct_last_update_post_date: 2024-06-28 last_seen_at: "2026-05-12T06:56:50.585Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake **Official Title:** Culturally-targeted Communication to Promote SARS-CoV-2 Antibody Testing in Saliva: Enabling Evaluation of Inflammatory Pathways in COVID-19 Racial Disparities **NCT ID:** [NCT04957082](https://clinicaltrials.gov/study/NCT04957082) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 666 - **Lead Sponsor:** Michigan State University - **Collaborators:** National Cancer Institute (NCI), Johns Hopkins University - **Conditions:** SARS-CoV2 Infection - **Start Date:** 2021-08-04 - **Completion Date:** 2022-12-19 - **CT.gov Last Update:** 2024-06-28 ## Brief Summary This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan. This iteration will consider individuals recruited from the Flint Registry and assess willingness to participate in a drive-up saliva sample collection taking place at a central location in Flint, Michigan. ## Detailed Description African Americans develop and die from SARS-CoV-2 infection more than any other racial group in the United States, including in majority African American cities such as Flint, Michigan. Addressing these disparities may be aided by SARS-CoV-2 antibody testing. However, African Americans may be reluctant to partake in conventional antibody testing programs due to medical mistrust and experiences with racism. This study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing. The central hypothesis is that African-Americans will be more receptive to antibody testing when benefits and limitations are communicated in a culturally effective manner. Our clinical trial aims are to 1) develop and compare effects of a general versus culturally-targeted video about antibody testing on African American and White Flint residents' antibody testing attitudes and uptake; 2) identify and compare effects of a general versus culturally-targeted video on activation of medical mistrust and racism-related cognition among African Americans when considering antibody testing. In collaboration with clinical and community partners, we have prepared and will evaluate general and culturally-targeted video tutorials about SARS-CoV-2 antibody testing. These brief videos will be distributed to the Flint community through the Flint Registry - a highly visible local health resource exchange. We will furnish an opportunity to engage salivary antibody screening and measure willingness to participate. In this study iteration, we will consider willingness to participate in a drive-up saliva sample collection that is taking place at a central location in Flint, Michigan. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** Yes ``` Inclusion Criteria: * African American or White, 18 or older, and enrolled in the Flint Registry Exclusion Criteria: * All who do not meet inclusion criteria. ``` ## Arms - **White Flint Registry: General** (ACTIVE_COMPARATOR) — White participants receive "general consumption" video information about SARS-CoV-2 antibody testing. - **African American Registry: General** (ACTIVE_COMPARATOR) — African American participants receive "general consumption" video information about SARS-CoV-2 antibody testing. - **African American Registry: Culturally Targeted** (EXPERIMENTAL) — African American participants receive culturally targeted video information about SARS-CoV-2 antibody testing. ## Interventions - **Culturally Targeted SARS-CoV-2 Communication** (BEHAVIORAL) — SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans. - **General SARS-CoV-2 Communication** (BEHAVIORAL) — SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information ## Primary Outcomes - **Number (Percentage) of Participants Requested to Participate in Saliva-based SARS-CoV-2 Antibody Testing** _(time frame: Immediately following didactic study portion and health communication randomization on day 1.)_ — Number (Percentage) of participants who respond "yes" to be included in offer to participate in no cost SAR-CoV-2 salivary antibody test. - **Number (Percentage) of Participants Who Requested Saliva-based SARS-CoV-2 Antibody Testing Participated in the Testing.** _(time frame: 8 weeks from the day of consenting to participate in the salivary-based SARS-CoV-2 antibody testing)_ — Number (Percentage) of participants that requested to participate in antibody testing who actually complete antibody testing. - **SARS-CoV-2 Antibody Testing Attitudes** _(time frame: Immediately following didactic study portion and health communication randomization on day 1.)_ — Submeasure of Theory of Planned Behavior Indicating extent of a favorable attitude SARS-CoV-2 towards antibody testing (Seven point Likert Rating, with higher scores indicating more favorable Attitudes). - **SARS-CoV-2 Antibody Testing Normative Beliefs** _(time frame: Immediately following didactic study portion and health communication randomization on day 1.)_ — Sub-measure of Theory of Planned Behavior Indicating extent to which believes other people are favorable towards SARS-CoV-2 towards antibody testing (Seven point Likert Rating, with higher scores indicating stronger Normative Beliefs). - **Antibody Testing Perceived Behavioral Control** _(time frame: Immediately following didactic study portion and health communication randomization on day 1.)_ — Sub-measure of Theory of Planned Behavior Indicating Self Efficacy to Complete Antibody Testing (Seven point Likert Rating, with higher scores indicating greater Perceived Behavioral Control). - **Antibody Testing Intentions** _(time frame: Immediately following didactic study portion and health communication randomization on day 1.)_ — Sub-measure of Theory of Planned Behavior indicating Intentions to Complete Antibody Testing (Seven point Likert Rating, with higher scores indicating stronger screening Intentions). - **Antibody Testing Anticipatory Racism** _(time frame: Immediately following didactic study portion and health communication randomization on day 1.)_ — Extent to which participants believe that racism-related factors would diminish the value of SARS-CoV-2 antibody testing for self (Seven-point Likert rating, with higher scores indicating greater Anticipatory Racism). ## Locations (1) - Flint Journal Building, Flint, Michigan, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.flint journal building|flint|michigan|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04957082.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04957082* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*